Maxim Group Maintains Buy on Capricor Therapeutics, Raises Price Target to $50

Benzinga · 1d ago
Maxim Group analyst Jason McCarthy maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $25 to $50.